BeiGene, Ltd. and Viatris Inc.: SG&A Spending Patterns Compared

SG&A Spending Patterns: A Tale of Two Companies

In the dynamic world of pharmaceuticals, BeiGene, Ltd. and Viatris Inc. present a fascinating study in contrasting SG&A (Selling, General, and Administrative) spending patterns over the past decade. Since 2014, BeiGene has seen a meteoric rise in its SG&A expenses, growing from a modest $7 million to a staggering $1.5 billion by 2023. This represents an astonishing increase of over 21,000%, reflecting the company's aggressive expansion and investment in its operations.

On the other hand, Viatris Inc., a stalwart in the industry, has maintained a more stable trajectory. Starting at $1.5 billion in 2014, its SG&A expenses have grown to $4.65 billion in 2023, marking a more measured increase of approximately 210%. This steady growth underscores Viatris's focus on sustainable development and operational efficiency.

These spending patterns highlight the strategic differences between a rapidly growing biotech firm and an established pharmaceutical giant.